VEMXAFPLNAAOGD-GOSISDBHSA-N
C34H31F3N6O7 — CID 58630173
Data last refreshed: (MolForge compound catalog, from PubChem)
About VEMXAFPLNAAOGD-GOSISDBHSA-N
VEMXAFPLNAAOGD-GOSISDBHSA-N (PubChem CID 58630173) has the molecular formula C34H31F3N6O7 and a molecular weight of 692.65 g/mol. Its IUPAC name is N-[(2R)-1-(1,3-benzodioxol-5-ylamino)-1-oxopropan-2-yl]-2-[6-[4-(dimethylcarbamoyl)phenyl]-7-oxo-3-(trifluoromethyl)-4,5-dihydropyrazolo[5,4-c]pyridin-1-yl]-5-methoxybenzamide.
Molecular Properties
| Compound Name | VEMXAFPLNAAOGD-GOSISDBHSA-N |
|---|---|
| PubChem CID | 58630173 |
| Molecular Formula | C34H31F3N6O7 |
| Molecular Weight | 692.65 g/mol |
| Exact Mass | 692.22 |
| IUPAC Name | N-[(2R)-1-(1,3-benzodioxol-5-ylamino)-1-oxopropan-2-yl]-2-[6-[4-(dimethylcarbamoyl)phenyl]-7-oxo-3-(trifluoromethyl)-4,5-dihydropyrazolo[5,4-c]pyridin-1-yl]-5-methoxybenzamide |
| SMILES | COc1ccc(-n2nc(C(F)(F)F)c3c2C(=O)N(c2ccc(C(=O)N(C)C)cc2)CC3)c(C(=O)N[C@H](C)C(=O)Nc2ccc3c(c2)OCO3)c1 |
| InChI | InChI=1S/C34H31F3N6O7/c1-18(30(44)39-20-7-12-26-27(15-20)50-17-49-26)38-31(45)24-16-22(48-4)10-11-25(24)43-28-23(29(40-43)34(35,36)37)13-14-42(33(28)47)21-8-5-19(6-9-21)32(46)41(2)3/h5-12,15-16,18H,13-14,17H2,1-4H3,(H,38,45)(H,39,44)/t18-/m1/s1 |
| InChIKey | VEMXAFPLNAAOGD-GOSISDBHSA-N |
| XLogP | 4.29 |
| TPSA | 144.33 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 9 |
| Rotatable Bonds | 8 |
| Heavy Atoms | 50 |
| Complexity | — |
Lipinski Rule of Five
1 violation
| Rule | Value |
|---|---|
| MW ≤ 500 | 692.65 |
| LogP ≤ 5 | 4.29 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 9 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 58630173 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.